Korean Circ J.  2020 Jan;50(1):35-37. 10.4070/kcj.2019.0348.

Risk Stratification by SYNTAX Score Systems in Current Percutaneous Revascularization Era

• Kim C

• KMID: 2465661
• DOI: http://doi.org/10.4070/kcj.2019.0348

Abstract

No abstract available.

MeSH Terms

Risk Assessment
Angioplasty, Balloon, Coronary
Coronary Artery Disease

Reference

1. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005; 1:219–227.

2. Yadav M, Palmerini T, Caixeta A, et al. Prediction of coronary risk by SYNTAX and derived scores: Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery. J Am Coll Cardiol. 2013; 62:1219–1230.

3. Capodanno D, Di Salvo ME, Cincotta G, Miano M, Tamburino C, Tamburino C. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease. Circ Cardiovasc Interv. 2009; 2:302–308.

4. Wykrzykowska JJ, Garg S, Girasis C, et al. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol. 2010; 56:272–277.

5. Garg S, Serruys PW, Silber S, et al. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers trial. JACC Cardiovasc Interv. 2011; 4:432–441.

6. Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013; 381:639–650.

7. Kang J, Han JK, Kang DY, et al. SYNTAX score and SYNTAX score II can predict the clinical outcomes of patients with left main and/or 3-vessel disease undergoing percutaneous coronary intervention in the contemporary cobalt-chromium everolimus-eluting stent era. Korean Circ J. 2020; 50:22–34.

8. Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019; 394:1325–1334.

9. Mäkikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016; 388:2743–2752.

10. Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med. 2016; 375:2223–2235.